For the last 20 years, the standard-of-care adjuvant treatment for resected pathologically defined high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) has been ...
Hello. It's Mark Kris from Memorial Sloan Kettering. Recently, I presented information about the published trials of neoadjuvant nivolumab chemotherapy vs chemotherapy, showing robust, disease-free ...
Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence? The following represents disclosure information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results